ASTRO 2020 to feature latest MRIdian clinical experience highlighting outcomes in tough to treat cancer

Auction Alert - Premier Medical Depot - Closing Dec 2nd - Bid on Over 365 Lots

ASTRO 2020 to feature latest MRIdian clinical experience highlighting outcomes in tough to treat cancer

Press releases may be edited for formatting or style | October 21, 2020 Rad Oncology
CLEVELAND, Oct. 21, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian® Linac MRI-guided radiation therapy system will be featured at the 2020 Annual Meeting of the American Society for Radiation Oncology (ASTRO), being held virtually October 24 to 28, 2020. The meeting will feature presentations that showcase the MRIdian system, including how clinicians use this cutting-edge Stereotactic MRI-Guided Adaptive Radiation Therapy (SMART) technology to tackle both tough-to-treat and ubiquitous cancer, expand clinical experience with the device, and impact patient outcomes.

At this year's virtual ASTRO meeting, nearly 40 scientific session presentations/posters will highlight the important role of MRIdian in cancer care, including data bolstering its clinical value in the treatment of pancreas, prostate and tough-to-treat tumors such as oligometastases and renal cancer. With the clarity provided by MRIdian's real-time imaging and automatic beam gating, physicians are equipped to account for anatomical changes and motion caused by respiration or other bodily processes to personalize treatment to the patient's unique needs.

Acibadem Maslak Hospital will present its data on MRIdian treatment for low- to intermedia-risk prostate cancer patients. This study complements the Amsterdam University Medical Centers studies on patients with intermediate- to high-risk prostate cancer, where no fiducials were required and which resulted in fewer grade 2 toxicities than published data*.

Servicing GE, Philips and Siemens CT equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

Wednesday October 28, 2:00 PM – 3:00 PM ET
PV 07 - Poster Q&A - Session 7 4130
Weill Cornell/NewYork-Presbyterian, the Miami Cancer Institute (MCI), and the Moffitt Cancer Center are among the institutions presenting on their experiences using SMART for pancreas cancer. Findings are expected to strengthen the current body of literature, with SMART helping clinicians drive positive patient outcomes and new insights on volumes and survivability.
Monday, October 26, 11:45 AM – 11:50 AM ET
QP 12 - GI 02 - Hypofractionation in GI Cancers
Monday, October 26, 2:00 PM – 3:00 PM ET
PV 04 - Poster Q&A - Session 4 3426, 3363, & 3325
Amsterdam University Medical Centers and MCI will share data on utilization of SMART for tough-to-treat tumors, including renal cancer and abdominal oligomets, treated with radiation therapy and immunotherapy.
Monday, October 26, 2:00 PM – 3:00 PM ET
PV 04 - Poster Q&A - Session 4 4407, 2405
As part of ASTRO's Innovation Hub, a dedicated space within the virtual platform to highlight new technologies and innovations, ViewRay will host two brief Innovation Hub presentations on MRIdian's capabilities and a presentation on workflow and efficiency by Justin Rineer, M.D., Radiation Oncologist at Orlando Health UF Health Cancer Center. The company will also host an Industry Expert Theater presentation featuring experts from the Dana -Farber/Brigham Women's Cancer Center discussing their MRIdian clinical experience:

You Must Be Logged In To Post A Comment